A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood

S. N. Markovic, W. K. Nevala, C. B. Uhl, Esteban Celis, D. J. McKean

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

One of the most difficult laboratory challenges in the field of therapeutic cancer vaccines has been the development of uncomplicated/reproducible methods for the quantification of vaccine immunization efficacy in peripheral blood of cancer patients. Existing methods are limited by lack of functional information (tetramers), difficulties with standardization/reproducibility [enzyme-linked immunosorbent spot (ELISPOT)] and reliance on endogenous (sample-specific) antigen presentation (cytokine flow cytometry). Herein we present a reproducible method utilizing an artificial antigen-presenting cell platform for flow cytometry-based quantification of the frequency and activation status of peptide-specific cytotoxic T lymphocytes. The methodology [currently presented for cytomegalovirus human leucocyte antigen (HLA)-A2 cognant peptide antigens] allows simultaneous ex vivo quantification of activated (cytokine-producing) and inactive tetramer-positive T cells following HLA class I/peptide/CD28 stimulation independent of endogenous antigen presentation. The simplicity and reliability of the assay provide for high-throughput applications and automation. The utility and application of this method are discussed.

Original languageEnglish (US)
Pages (from-to)438-447
Number of pages10
JournalClinical and Experimental Immunology
Volume145
Issue number3
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Cytotoxic T-Lymphocytes
Cytokines
Peptides
Antigen Presentation
HLA Antigens
Flow Cytometry
Immunosorbents
Cancer Vaccines
Automation
Antigen-Presenting Cells
Cytomegalovirus
varespladib methyl
Immunization
Vaccines
T-Lymphocytes
Antigens
Enzymes
Neoplasms
Therapeutics

Keywords

  • Artificial antigen-presenting cells
  • Cytomegalovirus
  • Immunity
  • T cells
  • Tolerance

ASJC Scopus subject areas

  • Immunology

Cite this

A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood. / Markovic, S. N.; Nevala, W. K.; Uhl, C. B.; Celis, Esteban; McKean, D. J.

In: Clinical and Experimental Immunology, Vol. 145, No. 3, 01.09.2006, p. 438-447.

Research output: Contribution to journalArticle

@article{4cf69ac3cd2c4c83be9ff985d367ebd9,
title = "A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood",
abstract = "One of the most difficult laboratory challenges in the field of therapeutic cancer vaccines has been the development of uncomplicated/reproducible methods for the quantification of vaccine immunization efficacy in peripheral blood of cancer patients. Existing methods are limited by lack of functional information (tetramers), difficulties with standardization/reproducibility [enzyme-linked immunosorbent spot (ELISPOT)] and reliance on endogenous (sample-specific) antigen presentation (cytokine flow cytometry). Herein we present a reproducible method utilizing an artificial antigen-presenting cell platform for flow cytometry-based quantification of the frequency and activation status of peptide-specific cytotoxic T lymphocytes. The methodology [currently presented for cytomegalovirus human leucocyte antigen (HLA)-A2 cognant peptide antigens] allows simultaneous ex vivo quantification of activated (cytokine-producing) and inactive tetramer-positive T cells following HLA class I/peptide/CD28 stimulation independent of endogenous antigen presentation. The simplicity and reliability of the assay provide for high-throughput applications and automation. The utility and application of this method are discussed.",
keywords = "Artificial antigen-presenting cells, Cytomegalovirus, Immunity, T cells, Tolerance",
author = "Markovic, {S. N.} and Nevala, {W. K.} and Uhl, {C. B.} and Esteban Celis and McKean, {D. J.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1111/j.1365-2249.2006.03157.x",
language = "English (US)",
volume = "145",
pages = "438--447",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood

AU - Markovic, S. N.

AU - Nevala, W. K.

AU - Uhl, C. B.

AU - Celis, Esteban

AU - McKean, D. J.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - One of the most difficult laboratory challenges in the field of therapeutic cancer vaccines has been the development of uncomplicated/reproducible methods for the quantification of vaccine immunization efficacy in peripheral blood of cancer patients. Existing methods are limited by lack of functional information (tetramers), difficulties with standardization/reproducibility [enzyme-linked immunosorbent spot (ELISPOT)] and reliance on endogenous (sample-specific) antigen presentation (cytokine flow cytometry). Herein we present a reproducible method utilizing an artificial antigen-presenting cell platform for flow cytometry-based quantification of the frequency and activation status of peptide-specific cytotoxic T lymphocytes. The methodology [currently presented for cytomegalovirus human leucocyte antigen (HLA)-A2 cognant peptide antigens] allows simultaneous ex vivo quantification of activated (cytokine-producing) and inactive tetramer-positive T cells following HLA class I/peptide/CD28 stimulation independent of endogenous antigen presentation. The simplicity and reliability of the assay provide for high-throughput applications and automation. The utility and application of this method are discussed.

AB - One of the most difficult laboratory challenges in the field of therapeutic cancer vaccines has been the development of uncomplicated/reproducible methods for the quantification of vaccine immunization efficacy in peripheral blood of cancer patients. Existing methods are limited by lack of functional information (tetramers), difficulties with standardization/reproducibility [enzyme-linked immunosorbent spot (ELISPOT)] and reliance on endogenous (sample-specific) antigen presentation (cytokine flow cytometry). Herein we present a reproducible method utilizing an artificial antigen-presenting cell platform for flow cytometry-based quantification of the frequency and activation status of peptide-specific cytotoxic T lymphocytes. The methodology [currently presented for cytomegalovirus human leucocyte antigen (HLA)-A2 cognant peptide antigens] allows simultaneous ex vivo quantification of activated (cytokine-producing) and inactive tetramer-positive T cells following HLA class I/peptide/CD28 stimulation independent of endogenous antigen presentation. The simplicity and reliability of the assay provide for high-throughput applications and automation. The utility and application of this method are discussed.

KW - Artificial antigen-presenting cells

KW - Cytomegalovirus

KW - Immunity

KW - T cells

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=33747411420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747411420&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2006.03157.x

DO - 10.1111/j.1365-2249.2006.03157.x

M3 - Article

VL - 145

SP - 438

EP - 447

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -